Drug Search Results
More Filters [+]

ORTD-1

Alternative Names: ortd-1, ortd 1, ortd1
Latest Update: 2023-04-17
Latest Update Note: PubMed Publication

Product Description

Orynotide ORTD-1 is being developed as a novel treatment for rheumatoid arthritis, COVID-19, and other systemic inflammatory diseases.

Mechanisms of Action: Immunomodulator

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous,Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Oryn Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ORTD-1

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Arthritis, Rheumatoid

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ORTD1-002

P1

Completed

Arthritis, Rheumatoid

2021-10-12

21%

Recent News Events